Induction of HA-1-specific cytotoxic T-cell clones parallels the therapeutic effect of donor lymphocyte infusion

被引:54
作者
Kircher, B
Stevanovic, S
Urbanek, M
Mitterschiffthaler, A
Rammensee, HG
Grünewald, K
Gastl, G
Nachbaur, D
机构
[1] Univ Innsbruck Hosp, Lab Tumour & Immunobiol, Div Haematol & Oncol,Dept Internal Med, Bone Marrow Transplantat Unit, A-6020 Innsbruck, Austria
[2] Univ Tubingen, Dept Immunol, Inst Cellular Biol, D-72074 Tubingen, Germany
[3] Univ Innsbruck Hosp, Dept Internal Med, Div Haematol & Oncol, Lab Mol Genet & Diagnost, A-6020 Innsbruck, Austria
[4] Austria Bone Marrow Donor Registry, Vienna, Austria
关键词
donor lymphocyte infusion; graft-versus-leukaemia effect; graft-versus-host disease; HA-1; minor histocompatibility antigen;
D O I
10.1046/j.1365-2141.2002.03536.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Donor lymphocyte infusions (DLI) can induce a graft-versus-leukaemia (GvL) reaction in patients with relapsed disease. However, the mechanisms involved in remission induction are not completely known. A patient with chemotherapy-refractory relapse 1 year after human leucocyte antigen (HLA)-identical, unrelated stem cell transplantation (SCT) for bcr/abl-positive common acute lymphoblastic leukaemia (ALL) received a DLI from the original donor, and achieved complete cytogenetic and molecular remission concomitantly with extensive graft-versus-host disease (GvHD). Seven CD8(+) , donor-derived, alloreactive T-cell clones were generated by stimulating post-DLI remission cells with the patient's pretransplant mature dendritic cells. The minor histocompatibility antigen (mHag) recognized by these T-cell clones was identified as HA-1, a mHag associated with acute GvHD after SCT. Our finding provides evidence of HA-1-associated GvL effects after DLI that paralleled the eradication of full-blown, chemotherapy-refractory ALL relapse after allogeneic SCT.
引用
收藏
页码:935 / 939
页数:5
相关论文
共 33 条
  • [1] Specific human cellular immunity to bcr-abl oncogene-derived peptides
    Bocchia, M
    Korontsvit, T
    Xu, Q
    Mackinnon, S
    Yang, SY
    Sette, A
    Scheinberg, DA
    [J]. BLOOD, 1996, 87 (09) : 3587 - 3592
  • [2] Donor leukocyte infusions in acute lymphocytic leukemia
    Collins, RH
    Goldstein, S
    Giralt, S
    Levine, J
    Porter, D
    Drobyski, W
    Barrett, J
    Johnson, M
    Kirk, A
    Horowitz, M
    Parker, P
    [J]. BONE MARROW TRANSPLANTATION, 2000, 26 (05) : 511 - 516
  • [3] Dazzi F, 1999, Curr Opin Hematol, V6, P394, DOI 10.1097/00062752-199911000-00007
  • [4] DEBUEGER M, 1992, J IMMUNOL, V149, P1788
  • [5] The minor histocompatibility antigen HA-1: A diallelic gene with a single amino acid polymorphism
    den Haan, JMM
    Meadows, LM
    Wang, W
    Pool, J
    Blokland, E
    Bishop, TL
    Reinhardus, C
    Shabanowitz, J
    Offringa, R
    Hunt, DF
    Engelhard, VH
    Goulmy, E
    [J]. SCIENCE, 1998, 279 (5353) : 1054 - 1057
  • [6] IDENTIFICATION OF A GRAFT-VERSUS-HOST DISEASE-ASSOCIATED HUMAN MINOR HISTOCOMPATIBILITY ANTIGEN
    DENHAAN, JMM
    SHERMAN, NE
    BLOKLAND, E
    HUCZKO, E
    KONING, F
    DRIJFHOUT, JW
    SKIPPER, J
    SHABANOWITZ, J
    HUNT, DF
    ENGELHARD, VH
    GOULMY, E
    [J]. SCIENCE, 1995, 268 (5216) : 1476 - 1480
  • [7] Eibl B, 1997, GENE CHROMOSOME CANC, V20, P215, DOI 10.1002/(SICI)1098-2264(199711)20:3<215::AID-GCC1>3.0.CO
  • [8] 2-5
  • [9] Evidence for a graft-versus-tumor effect in a patient treated with marrow ablative chemotherapy and allogeneic bone marrow transplantation for breast cancer
    Eibl, B
    Schwaighofer, H
    Nachbaur, D
    Marth, C
    Gachter, A
    Knapp, R
    Bock, G
    Gassner, C
    Schiller, L
    Petersen, F
    Niederwieser, D
    [J]. BLOOD, 1996, 88 (04) : 1501 - 1508
  • [10] RECOGNITION OF CLONOGENIC LEUKEMIC-CELLS, REMISSION BONE-MARROW AND HLA-IDENTICAL DONOR BONE-MARROW BY CD8+ OR CD4+ MINOR HISTOCOMPATIBILITY ANTIGEN-SPECIFIC CYTOTOXIC T-LYMPHOCYTES
    FABER, LM
    VANDERHOEVEN, J
    GOULMY, E
    OTTER, ALH
    VANLUXEMBURGHEIJS, SAP
    WILLEMZE, R
    FALKENBURG, JHF
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (02) : 877 - 883